Gilead Expects Fewer Payer Restrictions In 2015, Says 250,000 Could Be Treated In U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
Harvoni brings in sales of $2.1 billion during first quarter on market for HCV, but Gilead predicts greater access to therapy in 2015, possibly leading to higher sales.